Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: Final clinical analysis of the NICHE study.-MedSci.cn

Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: Final clinical analysis of the NICHE study.

Verschoor, YL; Van den Berg, JE; Beets, G; Sikorska, K; Aalbers, A; Van Lent, A; Kok, M; Schumacher, T; Van Leerdam, ME; Haanen, JBAG; Voest, EE; Chalabi, M

JOURNAL OF CLINICAL ONCOLOGY, 2022; 40 (16):

科室
- - 订阅+
  - 更多科室
工具
服务